---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-21-000024"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2021-07-29T23:59:59+00:00"
generated_at: "2026-06-30T01:18:44.674158+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vertex Q2 product revenues $1.79B (+18% YoY); raises FY 2021 guidance to $7.2-7.4B

## Summary
- Product revenues $1.793B, up 18% YoY; TRIKAFTA/KAFTRIO $1.256B led growth.
- GAAP net income $67M ($0.26 diluted EPS); non-GAAP net income $811M ($3.11 EPS).
- Raised full-year 2021 product revenue guidance to $7.2-7.4B from $6.7-6.9B.
- Recorded $900M payment to CRISPR in Q2 as R&D expense, impacting GAAP results.
- CTX001 dosed >45 patients; target enrollment in Phase 3 studies expected Q3 2021.

## SEC filing metadata
- accession: 0000875320-21-000024
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2021-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532021000024/0000875320-21-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532021000024/vrtx-20210729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-21-000024
- JSON: https://secwatch.observer/filing/0000875320-21-000024.json
- Plain text: https://secwatch.observer/filing/0000875320-21-000024.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.